Jean-Benoît le Polain de Waroux
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jean-Benoît le Polain de Waroux has a total of 205 co-authors. Here are the top co-authors by number of shared publications:
- Sebastien Knecht
AZ Sint-Jan Bruges, Belgium (S.K.).
13 shared publications Mattias Duytschaever
AZ Sint-Jan Hospital, Bruges, Belgium
10 shared publications- Rene Tavernier
Cardiology Department, AZ Sint-Jan Brugge , Ruddershove 10, Bruges 8000
10 shared publications - Mattias Duytschaever
Department of Cardiology, AZ Sint-Jan Hospital, Bruges, Belgium
9 shared publications - Benjamin De Becker
AZ Sint-Jan Brugge AV, Bruges Hospital, Bruges, Belgium
8 shared publications Gabriela Hilfiker
Department of Cardiology Sint‐Jan Hospital Brugge Belgium
6 shared publications
Latest Publications
- 1 May 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (5) , e016145
Rapid Atrial Pacing-Induced Wenckebach Atrioventricular Block: A Poor Predictor of Permanent Pacemaker Need Post-TAVR
BACKGROUND: The prognostic value of rapid atrial pacing (RAP)-induced Wenckebach atrioventricular block (W-AVB) as a diagnostic test for predicting permanent pacemaker implantation (PPI) after transcatheter aortic valve replacement (TAVR) remains unclear and requires further validation. The objective of this study was to evaluate the predictive value of RAP-induced W-AVB for PPI and sudden cardiac death within 30 days post-TAVR. METHODS: This prospective, investigator-initiated, multicenter study (PACE-TAVR) included 640 patients undergoing TAVR across 12 centers. RAP was performed before and after TAVR to assess for W-AVB. Using negative predictive values and negative likelihood ratios, the predictive value of W-AVB was evaluated for the primary end point: sudden cardiac death or guideline-based indications for PPI, including complete AVB or alternating bundle branch block (Class I), and preexisting conduction disturbances with new ECG changes, new-onset left bundle branch block, a positive electrophysiology study, or sinus node dysfunction (Class II). RESULTS: RAP was successfully performed post-TAVR in 556 patients, with RAP-induced W-AVB observed in 192 (34.5%). W-AVB was associated with baseline conduction disturbances, amiodarone use, pre-TAVR RAP-induced W-AVB, and anesthesia type. The primary end point was more frequent in patients with W-AVB (15.6% versus 9.3%; odds ratio, 1.80 [95% CI, 1.06–3.04]; P =0.029). However, the absence of W-AVB had a negative predictive value of only 90.7% and a poor negative likelihood ratio (0.79). The test’s utility declined in subgroups at high risk for PPI, including self-expanding valve recipients (odds ratio, 1.47 [95% CI, 0.84–2.58]; negative predictive value, 88.4%; negative likelihood ratio, 0.86) and patients with a baseline or new left bundle branch block (odds ratio, 1.14 [95% CI, 0.54–2.42]; negative predictive value, 81.3%; negative likelihood ratio, 0.95). CONCLUSIONS: RAP-induced W-AVB demonstrates limited utility in predicting post-TAVR PPI or sudden cardiac death, particularly in patients at high risk for PPI. Clinicians should be cautious when using this test for post-TAVR rhythm management. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05278585.
- 1 May 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (5) , e016145
Rapid Atrial Pacing-Induced Wenckebach Atrioventricular Block: A Poor Predictor of Permanent Pacemaker Need Post-TAVR
BACKGROUND: The prognostic value of rapid atrial pacing (RAP)-induced Wenckebach atrioventricular block (W-AVB) as a diagnostic test for predicting permanent pacemaker implantation (PPI) after transcatheter aortic valve replacement (TAVR) remains unclear and requires further validation. The objective of this study was to evaluate the predictive value of RAP-induced W-AVB for PPI and sudden cardiac death within 30 days post-TAVR. METHODS: This prospective, investigator-initiated, multicenter study (PACE-TAVR) included 640 patients undergoing TAVR across 12 centers. RAP was performed before and after TAVR to assess for W-AVB. Using negative predictive values and negative likelihood ratios, the predictive value of W-AVB was evaluated for the primary end point: sudden cardiac death or guideline-based indications for PPI, including complete AVB or alternating bundle branch block (Class I), and preexisting conduction disturbances with new ECG changes, new-onset left bundle branch block, a positive electrophysiology study, or sinus node dysfunction (Class II). RESULTS: RAP was successfully performed post-TAVR in 556 patients, with RAP-induced W-AVB observed in 192 (34.5%). W-AVB was associated with baseline conduction disturbances, amiodarone use, pre-TAVR RAP-induced W-AVB, and anesthesia type. The primary end point was more frequent in patients with W-AVB (15.6% versus 9.3%; odds ratio, 1.80 [95% CI, 1.06–3.04]; P =0.029). However, the absence of W-AVB had a negative predictive value of only 90.7% and a poor negative likelihood ratio (0.79). The test’s utility declined in subgroups at high risk for PPI, including self-expanding valve recipients (odds ratio, 1.47 [95% CI, 0.84–2.58]; negative predictive value, 88.4%; negative likelihood ratio, 0.86) and patients with a baseline or new left bundle branch block (odds ratio, 1.14 [95% CI, 0.54–2.42]; negative predictive value, 81.3%; negative likelihood ratio, 0.95). CONCLUSIONS: RAP-induced W-AVB demonstrates limited utility in predicting post-TAVR PPI or sudden cardiac death, particularly in patients at high risk for PPI. Clinicians should be cautious when using this test for post-TAVR rhythm management. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05278585.
- 13 January 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Combined Percutaneous Mechanical Aspiration and Transvenous Lead Extraction in CIED‐Related Endocarditis: A Case Report
Introduction: Current guidelines recommend complete removal of a cardiac implantable electronic device (CIED) in infective endocarditis (IE), with surgical extraction indicated for large vegetations (> 20–25 mm). Case: We report a 68‐year‐old patient with CIED‐related IE and a 3 × 3.5 cm lead vegetation successfully treated by percutaneous mechanical aspiration (PMA) using the FlowTriever system, followed by transvenous lead extraction (TLE). The combined approach achieved complete removal without complications or recurrence. Conclusion: This case highlights PMA as a feasible, less invasive alternative to surgery in selected high‐risk patients, enabling safe TLE by reducing vegetation size and embolic risk.
- 13 January 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Combined Percutaneous Mechanical Aspiration and Transvenous Lead Extraction in CIED‐Related Endocarditis: A Case Report
Introduction: Current guidelines recommend complete removal of a cardiac implantable electronic device (CIED) in infective endocarditis (IE), with surgical extraction indicated for large vegetations (> 20–25 mm). Case: We report a 68‐year‐old patient with CIED‐related IE and a 3 × 3.5 cm lead vegetation successfully treated by percutaneous mechanical aspiration (PMA) using the FlowTriever system, followed by transvenous lead extraction (TLE). The combined approach achieved complete removal without complications or recurrence. Conclusion: This case highlights PMA as a feasible, less invasive alternative to surgery in selected high‐risk patients, enabling safe TLE by reducing vegetation size and embolic risk.
- 1 December 2025
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 18 (12) , e014049
International Survey on Vein of Marshall Retrograde Ethanol Infusion
BACKGROUND: Retrograde ethanolization of the vein of Marshall (VOM) has been identified as an adjunct technique in the treatment of persistent atrial fibrillation (AF) and left atrial tachycardia, as stated in the last consensus statement on ablation of AF. However, there is a lack of high-volume data on the technique. METHODS: Through the collection of data from worldwide centers, we performed this international survey that aims to analyze the safety and procedural characteristics of VOM ethanolization in patients referred for treatment of AF or left atrial tachycardia. RESULTS: We included 5579 patients (66 years; range, 20–93) from 26 centers, who underwent VOM ethanolization between 2008 and 2024 for persistent AF (81%), paroxysmal AF (9%), or left atrial tachycardia (10%) under deep sedation (53%) or general anesthesia (47%). A concomitant mitral isthmus line was attempted in 79% of the cases, achieving mitral isthmus block in 98% of patients. There were 0.92% of periprocedural serious adverse events, including 0.09% of peri-procedural death (5 patients). Three patients developed hemodynamic collapse immediately after VOM ethanolization, causing the death of 1 due to anaphylactic shock. One patient died following surgical drainage of pericardial effusion 3 weeks after the procedure. The 3 other deaths were not directly related to VOM ethanolization. Pericardial effusion was observed in 123 patients (2.2%) at the time of or immediately after the procedure, requiring drainage in 20 patients (0.36%) and later in 32 additional patients (0.57%), including 5 (0.09%) requiring drainage. Pacemaker implantation was required in 2 patients (0.04%), 1 for high-grade atrioventricular block and 1 for sinus node dysfunction. CONCLUSIONS: This international survey shows that VOM ethanolization is predominantly performed in patients with persistent AF. It is associated with rare but potentially life-threatening adverse events. Mitral isthmus line ablation results in a very high rate of block when performed concomitantly.
- 1 December 2025
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 18 (12) , e014049
International Survey on Vein of Marshall Retrograde Ethanol Infusion
BACKGROUND: Retrograde ethanolization of the vein of Marshall (VOM) has been identified as an adjunct technique in the treatment of persistent atrial fibrillation (AF) and left atrial tachycardia, as stated in the last consensus statement on ablation of AF. However, there is a lack of high-volume data on the technique. METHODS: Through the collection of data from worldwide centers, we performed this international survey that aims to analyze the safety and procedural characteristics of VOM ethanolization in patients referred for treatment of AF or left atrial tachycardia. RESULTS: We included 5579 patients (66 years; range, 20–93) from 26 centers, who underwent VOM ethanolization between 2008 and 2024 for persistent AF (81%), paroxysmal AF (9%), or left atrial tachycardia (10%) under deep sedation (53%) or general anesthesia (47%). A concomitant mitral isthmus line was attempted in 79% of the cases, achieving mitral isthmus block in 98% of patients. There were 0.92% of periprocedural serious adverse events, including 0.09% of peri-procedural death (5 patients). Three patients developed hemodynamic collapse immediately after VOM ethanolization, causing the death of 1 due to anaphylactic shock. One patient died following surgical drainage of pericardial effusion 3 weeks after the procedure. The 3 other deaths were not directly related to VOM ethanolization. Pericardial effusion was observed in 123 patients (2.2%) at the time of or immediately after the procedure, requiring drainage in 20 patients (0.36%) and later in 32 additional patients (0.57%), including 5 (0.09%) requiring drainage. Pacemaker implantation was required in 2 patients (0.04%), 1 for high-grade atrioventricular block and 1 for sinus node dysfunction. CONCLUSIONS: This international survey shows that VOM ethanolization is predominantly performed in patients with persistent AF. It is associated with rare but potentially life-threatening adverse events. Mitral isthmus line ablation results in a very high rate of block when performed concomitantly.
- 14 October 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (48) , 5234-5236
Arrhythmic risk and advanced heart failure in dilated cardiomyopathy: a deadly tango
- 14 October 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (48) , 5234-5236
Arrhythmic risk and advanced heart failure in dilated cardiomyopathy: a deadly tango
- 25 September 2025
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 12 (1) , 16-27
Venous Ethanol Ablation as the Sole Treatment for Intramural Ventricular Arrhythmias
- 25 September 2025
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 12 (1) , 16-27
Venous Ethanol Ablation as the Sole Treatment for Intramural Ventricular Arrhythmias
- Open Access
- 1 July 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 9 (7) , ytaf322
Successfully escaping the pleura with the extra-vascular implantable cardioverter defibrillator lead: a case report
Background: Extra-vascular implantable cardioverter defibrillator (EV-ICD) is an emerging technique for ICD implantation with substernal lead placement. The system avoids the vasculature and can deliver anti-tachycardia and pause prevention pacing, with a generator size smaller than the existing subcutaneous device. While this device is now widely available, little is known about potential complications that may follow its implantation in real life context. Case summary: We report the case of a 46-year-old male with a history of non-ischaemic dilated cardiomyopathy, severely reduced left ventricular ejection fraction, and intravenous drug use who underwent EV-ICD implantation for primary prevention of sudden cardiac death. The device implantation was uncomplicated with initial satisfactory device parameters and fluoroscopic position. However, post-implant chest radiograph demonstrated lead dislodgement. Despite meticulous assessment on post-implantation CT, the exact position of the dislocated lead couldn’t be determined with certainty. Lead revision was performed at 1 month following implantation, and fluoroscopic assessment at this time revealed lead movement synchronous with respiration, raising suspicion that the lead was intra-pleural. A sheath was repositioned over the dislocated lead and contrast injected. Contrast dispersion confirmed the intra-pleural positioning of the lead and was subsequently used as landmark for the appropriate substernal retunnelling of the lead. At most recent follow-up, lead position on chest radiograph and device parameters were satisfactory. Discussion: Extra-vascular implantable cardioverter defibrillator lead placement and dislodgement within the pleural space can follow apparently uncomplicated implantation. Both cine-imaging and contrast injection can be used for accurate assessment of the lead position relative to the pleura and help successful reimplantation.
- 1 July 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 9 (7) , ytaf322
Open AccessSuccessfully escaping the pleura with the extra-vascular implantable cardioverter defibrillator lead: a case report
Background: Extra-vascular implantable cardioverter defibrillator (EV-ICD) is an emerging technique for ICD implantation with substernal lead placement. The system avoids the vasculature and can deliver anti-tachycardia and pause prevention pacing, with a generator size smaller than the existing subcutaneous device. While this device is now widely available, little is known about potential complications that may follow its implantation in real life context. Case summary: We report the case of a 46-year-old male with a history of non-ischaemic dilated cardiomyopathy, severely reduced left ventricular ejection fraction, and intravenous drug use who underwent EV-ICD implantation for primary prevention of sudden cardiac death. The device implantation was uncomplicated with initial satisfactory device parameters and fluoroscopic position. However, post-implant chest radiograph demonstrated lead dislodgement. Despite meticulous assessment on post-implantation CT, the exact position of the dislocated lead couldn’t be determined with certainty. Lead revision was performed at 1 month following implantation, and fluoroscopic assessment at this time revealed lead movement synchronous with respiration, raising suspicion that the lead was intra-pleural. A sheath was repositioned over the dislocated lead and contrast injected. Contrast dispersion confirmed the intra-pleural positioning of the lead and was subsequently used as landmark for the appropriate substernal retunnelling of the lead. At most recent follow-up, lead position on chest radiograph and device parameters were satisfactory. Discussion: Extra-vascular implantable cardioverter defibrillator lead placement and dislodgement within the pleural space can follow apparently uncomplicated implantation. Both cine-imaging and contrast injection can be used for accurate assessment of the lead position relative to the pleura and help successful reimplantation.
- Open Access
- 1 July 2025
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 18 (7) , e013780
How a Topological Mindset May Offer Extra Control During Mapping and Ablation of Left-Sided Reentrant Atrial Tachycardia
BACKGROUND: Reentry (macro or localized) is historically described as multiple pathways that are separated by barriers (either anatomic or functional) and involve active and passive loops (identified by electro-anatomic and entrainment mapping, EAM/ETM). Some reentrant atrial tachycardia (AT) cases are characterized by challenging activation patterns and unexpected ablation responses. A recent translational study, focusing on topology (TOP) and the role of boundaries, suggests that thinking topology within EAM/ETM might offer extra control during mapping and ablation of reentrant AT. We aimed to propose and prospectively validate a workflow (EAM/ETM+TOP) in which we integrate topological thinking within an EAM/ETM workflow for mapping and ablation of left-sided (left atrium) AT. METHODS: The integrated workflow was performed in 88 left atrium reentrant AT cases. After EAM/ETM, the number of loops and potential ablation strategy were verified against the number of critical and noncritical boundaries (critical boundary [CB], non-CB). Linear radiofrequency lesions were deployed to connect both CBs, preferably by one direct CB-CB line. RESULTS: EAM/ETM+TOP-based mapping was feasible in all cases and led to a diagnosis of a 2B topology with single-loop activation in 33 cases and a≥3B topology with dual-loop activation in 55 cases. In 87 out of 88 cases, subsequent ablation via a direct CB-CB approach (n=75), an indirect CB-non-CB-CB (n=9), or an indirect CB-non-CB-non-CB-CB approach (n=3) led to successful termination of AT. No unexpected changes in tachycardia cycle length occurred. After a median follow-up of 356 (inter-quartile range, 228–537) days, 16 patients experienced recurrence of AT (18%). CONCLUSIONS: Thinking topology within an EAM/ETM workflow may offer extra control during mapping and ablation of left-sided reentrant AT.
- 1 July 2025
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 18 (7) , e013780
Open AccessHow a Topological Mindset May Offer Extra Control During Mapping and Ablation of Left-Sided Reentrant Atrial Tachycardia
BACKGROUND: Reentry (macro or localized) is historically described as multiple pathways that are separated by barriers (either anatomic or functional) and involve active and passive loops (identified by electro-anatomic and entrainment mapping, EAM/ETM). Some reentrant atrial tachycardia (AT) cases are characterized by challenging activation patterns and unexpected ablation responses. A recent translational study, focusing on topology (TOP) and the role of boundaries, suggests that thinking topology within EAM/ETM might offer extra control during mapping and ablation of reentrant AT. We aimed to propose and prospectively validate a workflow (EAM/ETM+TOP) in which we integrate topological thinking within an EAM/ETM workflow for mapping and ablation of left-sided (left atrium) AT. METHODS: The integrated workflow was performed in 88 left atrium reentrant AT cases. After EAM/ETM, the number of loops and potential ablation strategy were verified against the number of critical and noncritical boundaries (critical boundary [CB], non-CB). Linear radiofrequency lesions were deployed to connect both CBs, preferably by one direct CB-CB line. RESULTS: EAM/ETM+TOP-based mapping was feasible in all cases and led to a diagnosis of a 2B topology with single-loop activation in 33 cases and a≥3B topology with dual-loop activation in 55 cases. In 87 out of 88 cases, subsequent ablation via a direct CB-CB approach (n=75), an indirect CB-non-CB-CB (n=9), or an indirect CB-non-CB-non-CB-CB approach (n=3) led to successful termination of AT. No unexpected changes in tachycardia cycle length occurred. After a median follow-up of 356 (inter-quartile range, 228–537) days, 16 patients experienced recurrence of AT (18%). CONCLUSIONS: Thinking topology within an EAM/ETM workflow may offer extra control during mapping and ablation of left-sided reentrant AT.
- 23 May 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (8) , 1733-1742
Prospective Evaluation of Superior Vena Cava Isolation as an Adjunct to Pulmonary Vein Re‐Isolation During Paroxysmal Atrial Fibrillation Repeat Procedures
Background: The superior vena cava (SVC) is a prominent non‐pulmonary vein trigger of atrial fibrillation (AF). Its isolation has been shown to be effective in paroxysmal AF (PAF) originating from SVC. Objective: In this study, focusing on repeat procedures for recurrent PAF post‐PVI, we aimed to evaluate the added value of empirical SVC isolation to PV antral re‐isolation, when at least one PV reconnection is demonstrated. Methods: Patients with recurrent PAF referred for redo procedures, and exhibiting PV reconnection, were randomly assigned to undergo either PVI alone (group 1) or PVI and SVC isolation (group 2). The primary outcome was the recurrence rate at 1‐year while procedural time, fluoroscopy time, complications rate, and the presence of scar during LA mapping were secondary outcomes. Results: Eighty‐two patients were randomized in the study (39 in group 1 and 43 in group 2). The median age was 65 ± 9 in group 1 and 62 ± 11 in group 2 ( p = 0.3). The time from first AF episode to the repeat procedure was 76 and 52 months, respectively ( p = 0.7). 31 patients in group 1 and 35 patients in group 2 had more than one reconnected vein. There were no significant differences in procedural and fluoroscopy times between groups. At 12‐months, freedom from atrial tachyarrhythmia was achieved in 69% patients in group 1% and 76% patients in group 2 (HR 0.7, 95% CI: 0.3–1.7). Conclusion: It is unknown whether empirical addition of SVC isolation to PVI improves freedom of recurrence for the treatment of recurrent PAF after previous PVI. Given the small study population, the addition of SVC isolation requires further investigation in a larger randomized trial.
- 23 May 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (8) , 1733-1742
Prospective Evaluation of Superior Vena Cava Isolation as an Adjunct to Pulmonary Vein Re‐Isolation During Paroxysmal Atrial Fibrillation Repeat Procedures
Background: The superior vena cava (SVC) is a prominent non‐pulmonary vein trigger of atrial fibrillation (AF). Its isolation has been shown to be effective in paroxysmal AF (PAF) originating from SVC. Objective: In this study, focusing on repeat procedures for recurrent PAF post‐PVI, we aimed to evaluate the added value of empirical SVC isolation to PV antral re‐isolation, when at least one PV reconnection is demonstrated. Methods: Patients with recurrent PAF referred for redo procedures, and exhibiting PV reconnection, were randomly assigned to undergo either PVI alone (group 1) or PVI and SVC isolation (group 2). The primary outcome was the recurrence rate at 1‐year while procedural time, fluoroscopy time, complications rate, and the presence of scar during LA mapping were secondary outcomes. Results: Eighty‐two patients were randomized in the study (39 in group 1 and 43 in group 2). The median age was 65 ± 9 in group 1 and 62 ± 11 in group 2 ( p = 0.3). The time from first AF episode to the repeat procedure was 76 and 52 months, respectively ( p = 0.7). 31 patients in group 1 and 35 patients in group 2 had more than one reconnected vein. There were no significant differences in procedural and fluoroscopy times between groups. At 12‐months, freedom from atrial tachyarrhythmia was achieved in 69% patients in group 1% and 76% patients in group 2 (HR 0.7, 95% CI: 0.3–1.7). Conclusion: It is unknown whether empirical addition of SVC isolation to PVI improves freedom of recurrence for the treatment of recurrent PAF after previous PVI. Given the small study population, the addition of SVC isolation requires further investigation in a larger randomized trial.
- Open Access
- 1 May 2025
- Published by Elsevier in Heart Rhythm
- Vol. 22 (11) , 2845-2856
Radiofrequency-aided venous ethanol vs optimized radiofrequency for primary and repeat ablation of left ventricular summit arrhythmias: A propensity score-matched comparison
- 1 May 2025
- Published by Elsevier in Heart Rhythm
- Vol. 22 (11) , 2845-2856
Open AccessRadiofrequency-aided venous ethanol vs optimized radiofrequency for primary and repeat ablation of left ventricular summit arrhythmias: A propensity score-matched comparison
- Open Access
- 8 January 2025
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 80 (2) , 124-134
Regional differences in survival after ICD implantation
The implantable cardioverter-defibrillator (ICD) remains the cornerstone in the prevention of sudden cardiac death. Cost-effectiveness depends on survival after implantation. In Belgium there are unexplained major differences in 3-year mortality after ICD implantation. Centre volume and socio-economic differences might affect survival after implantation. In total, 9647 patients underwent a first ICD implantation between February 2010 and 2016 in Belgium and were retrospectively compared for demographics, 30-day and 3-year mortality. Chi-squared and Mann-Whitney U tests were used to determine differences across centre volume. Low-volume centres treated patients with different characteristics and implanted more patients with ischaemic heart disease (50.2 vs 47.9%, p = 0.002), in primary prevention (66.7 vs 62.0%, p < 0.001) and with overall more comorbidities. Kaplan-Meier survival analysis showed a significant higher 3-year mortality in low-volume centres (16.3 vs 11.4%, p < 0.001). After adjudication with a multivariable Cox model, centre volume remained an independent predictor of 3-year mortality (low volume HR 1.300 [95% CI 1.124-1.504]. However similar 30-day mortality (0.6% in low vs 0.5% in high volume centres, p = 0.393) suggests that implantation related determinants alone are insufficient to explain the long-term survival difference. Socio-economic factors like regional average income (wealth) and overall survival (health) also were associated with the survival difference between low- and high-volume centres. There exist large survival differences after ICD implantation between implanting centres in Belgium that cannot only be explained by a volume-outcome effect. Centres size and characteristics are inhomogeneous and vary according to different socio-economic variables. Some of these variables are also significantly associated with survival and warrant further investigation.
- 8 January 2025
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 80 (2) , 124-134
Open AccessRegional differences in survival after ICD implantation
The implantable cardioverter-defibrillator (ICD) remains the cornerstone in the prevention of sudden cardiac death. Cost-effectiveness depends on survival after implantation. In Belgium there are unexplained major differences in 3-year mortality after ICD implantation. Centre volume and socio-economic differences might affect survival after implantation. In total, 9647 patients underwent a first ICD implantation between February 2010 and 2016 in Belgium and were retrospectively compared for demographics, 30-day and 3-year mortality. Chi-squared and Mann-Whitney U tests were used to determine differences across centre volume. Low-volume centres treated patients with different characteristics and implanted more patients with ischaemic heart disease (50.2 vs 47.9%, p = 0.002), in primary prevention (66.7 vs 62.0%, p < 0.001) and with overall more comorbidities. Kaplan-Meier survival analysis showed a significant higher 3-year mortality in low-volume centres (16.3 vs 11.4%, p < 0.001). After adjudication with a multivariable Cox model, centre volume remained an independent predictor of 3-year mortality (low volume HR 1.300 [95% CI 1.124-1.504]. However similar 30-day mortality (0.6% in low vs 0.5% in high volume centres, p = 0.393) suggests that implantation related determinants alone are insufficient to explain the long-term survival difference. Socio-economic factors like regional average income (wealth) and overall survival (health) also were associated with the survival difference between low- and high-volume centres. There exist large survival differences after ICD implantation between implanting centres in Belgium that cannot only be explained by a volume-outcome effect. Centres size and characteristics are inhomogeneous and vary according to different socio-economic variables. Some of these variables are also significantly associated with survival and warrant further investigation.